A Food and Drug Administration rebuke of televised comments made by Aegerion Pharmaceuticals Incs CEOwhich led the company to air a TV commercial correcting the statementswas prompted by complaints from a government drug reviewer according to emails viewed by The Wall Street Journal  The emails shed light on the regulators oversight of marketing in the Internet age where comments that might have aired once and been forgotten in the past can now easily be retrieved through a Google search 